Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Cell redox homeostasis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Endogenous Metabolite (5) Keap1-Nrf2 (1) Polo-like Kinase (PLK) (1) Reactive Oxygen Species (1) Sirtuin (4)
By Research Areas:	Cancer (7) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0150S

Nicotinamide-d4 1 Publications Verification Niacinamide-d₄; Nicotinic acid amide-d₄	Sirtuin Endogenous Metabolite	Neurological Disease Cancer
Nicotinamide-d₄ is the deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.

HY-113324

NADPH Maximum Cited Publications 10 Publications Verification	Endogenous Metabolite	Cancer
NADPH is an essential electron donor in organisms, providing reducing power for anabolic reactions and redox balance, with potential applications in electrosynthesis. The cellular NADPH homeostasis is associated with tumorigenesis. As a key factor in the cellular antioxidant system, NADPH can mediate cell death through its effects on oxidative stress. This approach, based on NADPH-regulated metabolism, holds promise for research in the field of cancer therapy .

HY-B0150S2

Nicotinamide-13C6 Niacinamide-¹³C₆; Nicotinic acid amide-¹³C₆	Endogenous Metabolite Sirtuin	Neurological Disease Cancer
Nicotinamide- ¹³C₆ is the ¹³C-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.

HY-B0150S1

Nicotinamide-15N,13C3 Niacinamide-¹⁵N,¹³C₃; Nicotinic acid amide-¹⁵N,¹³C₃	Endogenous Metabolite Sirtuin	Neurological Disease Cancer
Nicotinamide- ¹⁵N, ¹³C₃ is the ¹³C-labeled and ¹⁵N-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.

HY-W009356A

L-Cystine monohydrochloride	Biochemical Assay Reagents	Others
L-Cystine monohydrochloride is an amino acid. L-Cystine is converted to L-Cysteine in the body. Moreover, L-Cystine/L-Cysteine conversion system is a channel on the cell membrane, which can maintain the internal REDOX homeostasis of E. coli .

HY-113325R

NADP (Standard)	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
NADP (Standard) is the analytical standard of NADP. This product is intended for research and analytical applications. NADP is a coenzyme involved in cellular electron transfer reactions in biological metabolism, which is alternately oxidized (NADP+) and reduced (NADPH), and can maintain cellular redox homeostasis and regulate many biological events, including cellular metabolism. NADPH is a universal electron donor that provides reducing ability for synthetic metabolic reactions and redox balance. NADPH plays a multifunctional role in regulating inflammation, redox homeostasis, and synthetic metabolism processes . In Vitro:NADP can impair folate metabolism and nucleotide biosynthesis in HCT116 cells at high concentrations, leading to the cessation of proliferation and prioritizing cell survival . NADP forms NAADP through IL-8-driven CD38 to mobilize Ca ²⁺ and influence cell migration . NADP de novo synthesis mediated by NADK upregulation provides power for anabolic reaction and antioxidant system to promote breast cancer metastasis . NADP is upregulated in ROS generation mediated by hyperglycemia and IDPc induction, thereby protecting renal cells from oxidative stress .

HY-155784

SPC-180002	Sirtuin Reactive Oxygen Species Keap1-Nrf2	Cancer
SPC-180002 is a SIRT1/3 dual inhibitor, with IC₅₀ values of 1.13 and 5.41 μM, respectively. SPC-180002 disturbs redox homeostasis via ROS generation, which leads to an increase in both p21 protein stability and mitochondrial dysfunction. SPC-180002 strongly inhibits cell cycle progression and cancer cell growth. SPC-180002 activates the Nrf2 signaling pathway .

HY-161521

PLK1-IN-10	Polo-like Kinase (PLK)	Cancer
PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	1,117 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,117 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

1,117 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,117 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Type